Deal closing now drives Catalyst
- Catalyst agreed to be acquired by Angelini Pharma, so the stock is now mainly a deal-closing story.
- The Hetero patent settlement bars a FIRDAPSE generic until January 2035, removing the biggest prior legal risk.
- Q1 2026 revenue was $149.4 million, with FIRDAPSE still the largest product at $98.9 million.
- AGAMREE is the key growth product, with Q1 2026 net product revenue of $36.7 million.
- FYCOMPA is shrinking after generic entry, with Q1 2026 revenue down 61.3% from the prior-year period.
From patent fight to deal vote
Catalyst used to trade around one big question: would FIRDAPSE lose patent protection early? That risk changed on May 6, 2026, when Catalyst settled with Hetero, the last remaining FIRDAPSE challenger. Hetero cannot market a generic until January 2035.
On the same day, Catalyst announced a definitive merger agreement to be acquired by Angelini Pharma. That resets the thesis. The bull case is no longer about years of stand-alone growth. It is about the deal closing on time, expected in Q3 2026.
The business backdrop still matters. Q1 2026 showed $149.4 million of total revenue, AGAMREE growth, and lower cost of sales helped by the FIRDAPSE royalty step-down. Those facts make the asset base look cleaner for a buyer.
The bear case is now transaction risk. If stockholders vote no, regulators slow the deal, or another condition fails, the stock could fall below the deal price. The settled Hetero case gives the stand-alone company a stronger floor than before, but it would still be a major reset.
Small patient groups, high-value drugs
Catalyst is a commercial-stage biopharma company. It buys, develops, and sells drugs for rare diseases, mainly in the United States. These markets are small, but the drugs can carry high prices because there are few approved options.
The model depends on exclusivity. Patents, Orange Book listings, and orphan drug protections help keep generics away for a period of time. FIRDAPSE is the clearest example, since the Hetero settlement now protects the U.S. cash flow from generic entry until January 2035.
Revenue comes from direct drug sales. In Q1 2026, FIRDAPSE made up most of revenue, AGAMREE was the growth driver, and FYCOMPA was falling after its loss of exclusivity. That mix makes execution simple to follow, but it also makes each product outcome very important.
Two assets matter most
FIRDAPSE
FIRDAPSE treats Lambert-Eaton myasthenic syndrome, or LEMS. It generated $98.9 million of Q1 2026 net product revenue and remains the main source of cash.
AGAMREE
AGAMREE treats Duchenne Muscular Dystrophy, or DMD. It generated $36.7 million of Q1 2026 net product revenue and is the main growth asset.
FYCOMPA
FYCOMPA is an anti-epileptic drug. Catalyst stopped active marketing after loss of exclusivity, and Q1 2026 revenue fell 61.3% from the prior-year period.
Rare disease licensing
Catalyst also depends on finding or licensing rare disease drugs that can fit its sales model. This is not the near-term stock driver while the Angelini deal is pending.
Q1 revenue is still concentrated
Catalyst reports one business segment, so this mix uses Q1 2026 net product revenue by product. FIRDAPSE was about two thirds of revenue, which keeps product concentration high even as AGAMREE grows.
What could break the setup
Angelini merger does not close
High impact · Medium oddsThe main risk is no longer the Hetero patent case. It is whether the Angelini Pharma merger closes. The deal still needs stockholder approval and other customary conditions, and the company warned that failure or delay could hurt operations and the stock price.
FIRDAPSE concentration remains high
High impact · Medium oddsFIRDAPSE produced $98.9 million of Q1 2026 revenue out of $149.4 million total revenue. The Hetero settlement helps protect the product through 2034, but the company is still highly tied to one drug.
AGAMREE launch slows
Medium impact · Medium oddsAGAMREE is the product that offsets FYCOMPA erosion and broadens the company beyond FIRDAPSE. If doctors or payers adopt it more slowly, the growth profile becomes less attractive. That would matter more if the Angelini deal failed.
FYCOMPA erosion speeds up
Medium impact · High oddsFYCOMPA has already lost exclusivity, and generic competition is hurting sales. Q1 2026 FYCOMPA revenue was $13.8 million and fell 61.3% from the prior-year period. This is expected pressure, but a faster fall can reduce near-term cash flow.
Drug pricing or tariff pressure
Medium impact · Medium oddsCatalyst has disclosed risks from possible pharmaceutical import tariffs and broader U.S. drug pricing reform. These risks could pressure profit if they affect manufacturing costs or allowed drug prices. The exact impact is still uncertain.
In one breath
What does Catalyst Pharmaceuticals do?
Catalyst sells approved drugs for rare diseases. Its main products are FIRDAPSE for LEMS, AGAMREE for DMD, and FYCOMPA for epilepsy.
Why did the CPRX thesis change in 2026?
Catalyst settled the last FIRDAPSE patent challenge with Hetero and agreed to be acquired by Angelini Pharma. That moved the stock story from patent litigation risk to merger closing risk.
What is the biggest risk for CPRX now?
The biggest risk is that the Angelini Pharma merger does not close or is delayed. If that happens, the stock could trade down from the deal price, even though the FIRDAPSE settlement gives the business a better stand-alone base.
Is FIRDAPSE still important after the settlement?
Yes. FIRDAPSE was $98.9 million of Q1 2026 revenue, making it the largest product by far. The Hetero settlement matters because it blocks that generic challenger until January 2035.